by Croft SL, Engel J. Trans R Soc Trop Med Hyg, December 2006,100 Suppl 1:S4-8. Epub 2006 Aug 14.
Summary: Miltefosine (hexadecylphosphocholine, ImpavidoTM), a novel antiprotozoal drug used for the treatment of visceral and cutaneous leishmaniasis, was identified and evaluated independently in the early 1980s as a potential anticancer drug in Germany and as an antileishmanial drug in the UK. Miltefosine is active against most Leishmania species, including those that cause cutaneous disease.
